Cardiac Electrophysiology Section, Division of Cardiology, Department of Medicine, University of California, San Diego, San Diego, California.
Baim Institute for Clinical Research, Boston, Massachusetts.
Am J Cardiol. 2021 Sep 15;155:32-39. doi: 10.1016/j.amjcard.2021.06.011. Epub 2021 Jul 18.
This study sought to evaluate inappropriate prescribing practices in an atrial fibrillation (AF) population, as outlined by the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults with Atrial Fibrillation or Atrial Flutter document. The 2016 AF quality measures document specified medications to avoid in certain AF populations, including aspirin and anticoagulant combination therapy in patients without cardiovascular disease, and non-dihydropyridine calcium channel blockers in patients with reduced ejection fraction. Using data from the NCDR PINNACLE registry, a national outpatient cardiology practice registry, we assessed rates of inappropriate prescription of two types of medications among AF outpatients from 5/1/2008-5/1/2016. Overall rates of inappropriate prescription and variation by practice were calculated. Patient and practice factors associated with inappropriate prescription were assessed in adjusted analyses. A total of 107,759 of 658,250 (16.4%) patients without cardiovascular disease were inappropriately prescribed an antiplatelet and anticoagulant together, and 5,731 of 150,079 (3.8%) patients with reduced ejection fraction were inappropriately prescribed a non-dihydropyridine calcium channel blocker. Overall, 14.8% of AF patients were prescribed medications that were not recommended. Both patient and practice factors were associated with inappropriate prescribing, and the adjusted practice-level median odds ratio for inappropriate prescription was 1.70 (95% CI: 1.61-1.82), indicating a 70% likelihood that 2 random practices would treat identical AF patients differently. In a large registry of AF patients treated in cardiology practices, overall rates of inappropriate prescription practices, as defined by the 2016 AF quality measures, were relatively low, but significant practice variation was present.
本研究旨在评估 2016 年 ACC/AHA 成人房颤或房扑临床绩效和质量措施文件中概述的房颤人群中不适当的处方实践。2016 年房颤质量措施文件规定了某些房颤人群中应避免使用的药物,包括无心血管疾病的患者中阿司匹林和抗凝联合治疗,以及射血分数降低的患者中使用非二氢吡啶类钙通道阻滞剂。利用 NCDR PINNACLE 注册中心(一个全国性的门诊心脏病学实践注册中心)的数据,我们评估了 2008 年 5 月 1 日至 2016 年 5 月 1 日期间,房颤门诊患者两种类型药物不适当处方的比例。计算了不适当处方的总体比例和实践差异。在调整分析中评估了与不适当处方相关的患者和实践因素。在无心血管疾病的 658250 名患者中,共有 107759 名患者被不恰当地联合开具抗血小板和抗凝药物,在射血分数降低的 150079 名患者中,有 5731 名患者被不恰当地开具非二氢吡啶类钙通道阻滞剂。总的来说,14.8%的房颤患者服用了不推荐的药物。患者和实践因素都与不适当的处方有关,调整后的实践水平中位数比值比(OR)为 1.70(95%可信区间:1.61-1.82),这表明两个随机实践对相同的房颤患者进行不同治疗的可能性为 70%。在一个大型的房颤患者注册中心中,按照 2016 年房颤质量措施的定义,不适当处方的总体比例相对较低,但存在显著的实践差异。